Two rationales prompted us to evaluate COAM in EAE: (i) the suggestion[16] that COAM induces endogenous IFN-β with known therapeutic effects in MS and EAE and (ii) the fact that COAM protected against immunopathologies observed in acute lethal virus infection models[17,19]. This evidence concerns the gene IFNB1 and myeloid sarcoma.